Pealkiri: 

Testicular cancer in Europe and the USA: survival still rising among older patients

Autorid: Verhoeven R, Gondos A, Janssen-Heijnen M
Väljaandja/tellija: Ann Oncol
Märksõnad: kasvajad, mehed, Euroopa, elulemus, suremus, mittenakkushaigused
Välja antud: 2013
Tüüp: Teaduslik artikkel/kogumik
Viide: Verhoeven RH, Gondos A, Janssen-Heijnen ML, et al. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2013 Feb;24(2):508-13.
Link: http://annonc.oxfordjournals.org/content/24/2/508.long
Alamvaldkonnad:Mittenakkushaigused
Tervisenäitajate siseriiklik ja rahvusvaheline võrdlus
Kirjeldus: BACKGROUND: Despite high curability, some testicular cancer (TC) patient groups may have increased mortality. We provide a detailed age- and histology-specific comparison of population-based relative survival of TC patients in Europe and the USA. Design Using data from 12 European cancer registries and the USA Surveillance, Epidemiology and End Results 9 database, we report survival trends for patients diagnosed with testicular seminomas and nonseminomas between 1993-1997 and 2003-2007. Additionally, a model-based analysis was used to compare survival trends and relative excess risk (RER) of death between Europe and the USA adjusting for differences in age and histology. RESULTS: In 2003-2007, the 5-year relative survival of patients with testicular seminoma was at least 98% among those aged <50 years, survival of patients with nonseminoma remained 3%-6% units lower. Despite improvements in the relative survival of nonseminoma patients aged ¿ 50 years by 13%-18% units, survival remained markedly lower than the survival of seminoma patients of the same age. Model-based analyses showed increased RERs for nonseminomas, older, and European patients. Conclusions: There remains little room for survival improvement among testicular seminoma patients, especially for those aged <50 years. Older TC patients remain at increased risk of death, which seems mainly attributable to the lower survival among the nonseminoma patients.